ChemGenex acquires leukaemia drug outright
Wednesday, 11 June, 2008
ChemGenex (ASX: CXS) has bought the rights to the drug omacetaxine the drug omacetaxine mepesuccinate outright from Stragen Pharma, meaning the company can now sell the drug directly in Europe.
The deal negates the need for ChemGenex to offer royalty payments on sales of the drug, which was developed partly using Stragen intellectual property.
Stragen will acquire over 37 million ChemGenex shares as payment.
Omacetaxine is a treatment for patients with chronic myeloid leukaemia with the T315I mutation.
There is currently no commercially available treatment for this form of leukaemia, but ChemGenex is about to wrap up its phase II/III trial of omacetaxine.
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
Saliva-based biosensor could improve heart failure detection
Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...
